BMC Women's Health最新文献

{"title":"Good long-term results of sacral neuromodulation for endometriosis related chronic pelvic pain.","authors":"Adrian Zegrea, Emilia Ojala, Jaan Kirss, Pia Suvitie, Pirita Varpe, Johanna Mäkelä-Kaikkonen, Tero Rautio, Jaana Seikkula, Mika Ukkonen, Maija Lavonius, Tarja Pinta","doi":"10.1186/s12905-025-03699-y","DOIUrl":"10.1186/s12905-025-03699-y","url":null,"abstract":"<p><strong>Background: </strong>Sacral neuromodulation (SNM) is an established therapy in urology and gastroenterological surgery for treatment of overactive bladder symptoms, urge urinary incontinence or fecal incontinence. SNM has also been used with good results in patients with chronic pelvic pain (CPP). Our aim was to analyze long-term results of SNM in Finnish patients with endometriosis related CPP.</p><p><strong>Methods: </strong>This is a register-based retrospective study including all the endometriosis patients treated with SNM for CPP in Finland between 2004 and 2017. There were four centers where these procedures were performed, two University Hospitals and two Central Hospitals. Long-term results were assessed by phone interview in spring 2021.</p><p><strong>Results: </strong>A total of 16 women with endometriosis, with a median age of 39 (25-50) years, underwent SNM treatment for chronic pelvic pain (CPP), with the median follow-up time of 73 (48-85) months. The Implantable Pulse Generator (IPG) was implanted to 14 patients (88%). By the end of the follow-up period, 10 patients (62,5% of all patients and 71% of those who received IPG) had a functional SNM. Pain was assessed by numeral rating scale (NRS) and decreased from a median of 7.4 (3.6-10) to 2.3 (0-6.5).</p><p><strong>Conclusions: </strong>SNM could be a good option in the treatment of endometriosis related chronic pelvic pain when standard therapy is not enough.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"162"},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying key palmitoylation-associated genes in endometriosis through genomic data analysis.","authors":"Jinyan Kai, Jiaqi Su, Yinping You, Xiaoliang Liang, Haitao Huang, Jie Fang, Qiong Chen","doi":"10.1186/s12905-025-03697-0","DOIUrl":"10.1186/s12905-025-03697-0","url":null,"abstract":"<p><strong>Background: </strong>Palmitoylation, a post-translational lipid modification, has garnered increasing attention for its role in inflammatory processes and tumorigenesis. Emerging evidence suggests a potential association between palmitoylation and inflammatory responses in the pathogenesis of endometriosis. However, the precise mechanistic interplay remains elusive, necessitating further investigation.</p><p><strong>Methods: </strong>This study integrated transcriptomic analysis and Mendelian randomization (MR) to identify a causal gene set implicated in endometriosis. Differentially expressed genes (DEGs) were first identified in the training dataset using the limma package in R. Weighted gene co-expression network analysis (WGCNA) was subsequently performed, leveraging Single Sample Gene Set Enrichment Analysis (ssGSEA)-derived scores of palmitoylation-related genes (PRGs) as phenotypic traits to identify key modular genes. The intersection of these key modular genes with DEGs yielded a refined gene set. Machine learning algorithms were then applied to further optimize gene selection, followed by external validation, immune infiltration analysis, RNA network construction, and exploration of potential targeted drug candidates.</p><p><strong>Results: </strong>Through a rigorous screening process, VRK1, GALNT12, and RMI1 emerged as key genes associated with palmitoylation, exhibiting significant downregulation in endometriosis samples (P < 0.05), indicative of a potential protective role. Immune infiltration analysis further revealed strong correlations between these genes and M2 macrophages as well as resting Natural Killer (NK) cells. Additionally, investigations into the targeted RNA network and drug association profiling provided novel insights, laying the groundwork for future high-quality validation studies.</p><p><strong>Conclusions: </strong>This study employed a comprehensive analytical framework to identify palmitoylation-associated key genes in endometriosis. The integration of immunoinfiltration analysis, RNA network construction, and drug association profiling offers valuable insights for advancing clinical diagnostics, disease monitoring, and therapeutic development in endometriosis.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"161"},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Handgrip strength and menopause are associated with cardiovascular risk in women with obesity: a cross-sectional study.","authors":"Jaqueline de Paula Chaves Freitas, Joyce Noelly Vitor Santos, Daniela Barreto de Moraes, Gabriele Teixeira Gonçalves, Leonardo Augusto da Costa Teixeira, Maria Thereza Otoni Figueiró, Tamara Cunha, Vanessa Kelly da Silva Lage, Ana Lúcia Danielewicz, Pedro Henrique Scheidt Figueiredo, Henrique Silveira Costa, Alessandro Sartorio, Thyago José Silva, Fidelis Antônio da Silva Júnior, Cheyenne Alves Fonseca, Elizabethe Adriana Esteves, Ana Cristina Rodrigues Lacerda, Vanessa Amaral Mendonça","doi":"10.1186/s12905-025-03702-6","DOIUrl":"10.1186/s12905-025-03702-6","url":null,"abstract":"<p><strong>Background: </strong>While physical performance is closely linked to cardiovascular health, further research is essential to elucidate the association of physical tests in the early screening for cardiovascular risk (CVR), underscoring the potential for these assessments to enhance preventive healthcare strategies.</p><p><strong>Objectives: </strong>To investigate the association between the Handgrip Strength (HGS) test and CVR in women with obesity, as well as to evaluate the predictive value of the HGS test as a CVR screening tool in this population.</p><p><strong>Methods: </strong>Fifty-five eligible women with obesity, aged 40 to 65 years, were studied. The Framingham Global Risk Score was used to classify participants into low-risk and moderate/high-risk groups. Dual X-ray Absorptiometry was used to assess body composition. Additionally, clinical and biochemical parameters, along with HGS, were evaluated. Data were analyzed using the logistic regression analysis, and the positive and negative predictive values were calculated; accuracy was defined through the ROC curve and the Youden index. Statistical significance was set at 5%.</p><p><strong>Results: </strong>The prevalence of the moderate/high CVR was 49%. The menopause [0.14 (0.03-0.52), p = 0.003] and handgrip strength [0.90 (0.82-0.99), p = 0.046] were associated with cardiovascular risk, independent of the clinical and biochemical parameters. The optimal cutoff points for screening CVR were ≤ 37.8 kg for HGS [AUC = 0.73 (0.59-0.84), p = 0.003].</p><p><strong>Conclusion: </strong>HGS and menopause are significantly associated with CVR in women with obesity, highlighting the importance of considering physical evaluation in early clinical screening for CVR. The simple measure of HGS emerged as a promising tool for cardiovascular prevention in this population.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"157"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of cervicovaginal microbiota as risk factor for cervical cancer in Sub-Saharan Africa: a systematic review and meta-analysis : By.","authors":"Monique Iheoma Ajah, Marie Esther Uju Dibua, Leonard Ogbonna Ajah, Nnamdi Vincent Chigor, Christian Kelechi Ezeh, George Uchenna Eleje, Fidelis Onyekachi Igwe","doi":"10.1186/s12905-025-03688-1","DOIUrl":"10.1186/s12905-025-03688-1","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the association between cervico-vaginal microbiota and cervical cancer in Sub-Saharan Africa.</p><p><strong>Study design: </strong>Systematic Review and Meta-Analysis.</p><p><strong>Method: </strong>The databases, PubMed and African Journal Online (AJOL), as well as Google Scholar, were accessed. All primary studies (cross-sectional, cohort and case control) that reported cervical cancer, risk factors and cervico-vaginal microbiota in Sub-Saharan Africa, which were written in English language, were screened. Methodological and quality assessment of included studies was carried out using Joanna Briggs Institute (JBI) quality assessment tool. Random effects model meta-analysis was performed using MedCalc statistical software version 20.0.1 to evaluate the pooled prevalence of cervico-vaginal microbiota and prevalence was determined using the Freeman-Tukey double arcsine transformation. Heterogeneity between studies was assessed using the I-squared (I²) test and publication bias evaluated using Egger's statistical test. The study protocol was registered with the PROSPERO database (No: CRD42024495232).</p><p><strong>Results: </strong>The review involved screening of a total of 1,151 articles and 15 articles, which met the inclusion criteria, were finally used for the review and meta-analysis. Cervico-vaginal risk factors noted in our study comprised infection with high risk human papilloma virus (hrHPV), human Immune virus (HIV), Trichomonas vaginalis, Porphyromonas, Prevotella, and Anaeromonas. The pooled prevalence of HPV in the included studies was 40% (95% Confidence interval [CI]- 24%, 56%) and pooled prevalence of HIV as a risk factor was 19% (95% CI- 3%, 44%). For each individual meta-analysis, high heterogeneity was observed with I² of 98.97 (HPV) and 99.33 (HIV) at p-values ≤ 0.01. Egger's tests for regression intercept in funnel plots indicated no evidence of publication bias while JBI result showed high quality of included articles.</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis revealed that cervico-vaginal microbiota, such as Porphyromonas, Prevotella, and Trichomonas vaginalis, along with high-risk HPV and HIV infection, increase cervical cancer risk in Sub-Saharan Africa. To reduce this burden, integrating microbiota management, sexual health education and HPV vaccination, is crucial.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"160"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor size and stage assessment accuracy of MRI and ultrasound versus pathological measurements in early breast cancer patients.","authors":"Yuanyuan Liu, Xuerui Liao, Yakun He, Fawei He, Jing Ren, Peng Zhou, Xin Zhang","doi":"10.1186/s12905-025-03679-2","DOIUrl":"10.1186/s12905-025-03679-2","url":null,"abstract":"<p><strong>Background: </strong>Accurate size and stage estimation is important to monitor tumor response and plan further treatment in breast cancer patients undergoing neoadjuvant chemotherapy. To evaluate the accuracy of imaging findings [ultrasound (US) and magnetic resonance imaging (MRI)] for tumor size and stage estimations in early breast cancer patients and to elucidate the factors influencing tumor stage assessment.</p><p><strong>Methods: </strong>We retrospectively enrolled consecutive women having pathologically confirmed breast cancer (stage T1/T2, 199 patients and 201 lesions) and preoperative records available for both US and MRI. The concordance between imaging-determined and pathological tumor size and stage was explored. The McNemar's test was conducted to compare the concordance between imaging-determined tumor size and imaging-determined tumor stage. Multivariate logistic regression was used to analyze the factors that influenced the accuracy.</p><p><strong>Results: </strong>The concordance between US-determined and pathological tumor size (71.1%) was comparable to MRI-pathology concordance (72.6%). MRI-determined stage concordance (73.6%) was comparable to US-determined stage concordance (69.2%). Tumors with a larger pathological size, were more likely to be underestimated by US or MRI in terms of tumor size and stage (all P < 0.05).</p><p><strong>Conclusion: </strong>Tumor size and tumor stage concordance did not significantly differ between US and MRI in early breast cancer patients; US could be the first choice for tumor size estimation and tumor staging.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"159"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis.","authors":"Zhang Ying, Liu Linxun, Zhao Kechang, Wang Xiaowu, Gengzhi Huazhen, Ma Zhijun","doi":"10.1186/s12905-025-03610-9","DOIUrl":"10.1186/s12905-025-03610-9","url":null,"abstract":"<p><strong>Background: </strong>The optimal duration of extended endocrine therapy (ET) for women with hormone receptor-positive (HR-positive) early-stage postmenopausal breast cancer remains uncertain. This meta-analysis systematically evaluated the optimal time to prolong aromatase inhibitors ( AIs) therapy for postmenopausal early stage breast cancer who received initial endocrine therapy.</p><p><strong>Methods: </strong>PubMed, Web of Science, Ovid, Scopus, EmBase, and Cochrane Library were searched for randomized controlled trials (RCTs) using keywords related to breast cancer, HR-positive, AIs, and tamoxifen (TAM). Disease-free survival (DFS) was used as the primary endpoint. Meta-analysis was performed using STATA 16.0 and Revman 5.4 statistical software. Hazard ratio (HR) with its corresponding 95% confidence intervals (CI) was used as an effective indicator to assess DFS, OS, and subgroups of extended ET. Relative ratio (RR) was used to assess adverse events.</p><p><strong>Results: </strong>The study included four RCTs involving 8,748 patients with HR-positive breast cancer. Pooled data showed an improvement in DFS when extending endocrine therapy from 5 to 7-8 years (HR = 0.82, 95% CI: 0.73 ~ 0.93), especially in patients with tumor size ≥ 2 cm (HR = 0.69, 95% CI: 0.49 ~ 0.98), estrogen receptor (ER) and progesterone receptor (PR) positive (HR = 0.77, 95% CI: 0.67 ~ 0.89), human epidermal growth factor receptor 2 (HER-2) positive or negative (HR = 0.85, 95% CI: 0.74 ~ 0.97; HR = 0.44, 95% CI: 0.22 ~ 0.89) and previous chemotherapy (HR = 0.80, 95% CI: 0.68 ~ 0.95). However, DFS has not improved with the extension from 7-8 to 10 years (HR = 0.97, 95% CI: 0.85 ~ 1.10). Furthermore, we found no significant difference in overall survival (OS), adverse events (AEs) analysis revealed a significant increase in the incidence of arthralgia, osteoporosis, bone fractures and asthenia after extended AIs.</p><p><strong>Conclusions: </strong>The proportion of patients with breast cancer receiving ET extended beyond 5 years has increased, while the extension of AIs treatment from 5 to 7-8 years may be an option for high-risk patients with well-tolerated tumor size ≥ 2 cm, HR-positive, and previous chemotherapy. However, a variety of adverse events may accompany ET therapy, the identification of factors that may benefit breast cancer patients requires further randomized controlled studies.</p><p><strong>Prospero registration number: </strong>CRD42022335497.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"156"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Informational needs related to menstrual literacy among Dutch women: a focus group study.","authors":"Lisa Zuidema, Eveline M van Luik, Manna A Alma, Jaklien C Leemans, Marlies Y Bongers, Peggy M A J Geomini","doi":"10.1186/s12905-025-03694-3","DOIUrl":"10.1186/s12905-025-03694-3","url":null,"abstract":"<p><strong>Background: </strong>Menstruation remains a taboo topic that is rarely discussed openly, even though nearly half of the world's population experiences it. Studies have shown that women wish to have more information about menstrual care worldwide. It is therefore crucial to break the taboo and support women in their quest for information. This study aims to investigate informational needs related to menstruation among Dutch women, in order to improve menstrual literacy.</p><p><strong>Methods: </strong>A qualitative exploratory design with focus group discussions was used. Participants were recruited at the gynaecology outpatient clinic of Máxima MC and through social media posts. A total of 24 Dutch women (aged between 20 and 62 years), who currently menstruate or have menstruated, participated in three focus group discussions. A thematic analysis was used to analyse the data.</p><p><strong>Results: </strong>Participants indicated that schools or family members had not provided them with sufficient information about menstruation prior to their menarche. This lack of information resulted in shame, taboos, and bullying. Furthermore, difficulties in communicating about menstrual complaints with friends, family and medical professionals were reported, resulting in a lack of information about which complaints are normal and when to seek help. Participants suggested creating an easily accessible online platform, categorized according to life stage (for example, menarche, midlife, towards menopause).</p><p><strong>Conclusions: </strong>This qualitative study shows that Dutch women perceive information regarding menstruation as inadequate. It is recommended to re-evaluate menstrual education in school and combining information in one practical, patient-oriented website. For clinicians, it is important to realize menstrual knowledge of patients may be minimal and thus to support their patients in accessing reliable sources.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"158"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of SMOC2 in adenomyosis: implications for ECM remodeling and EMT pathogenesis.","authors":"Lei-Na Wang, Li Ren, Lin Li, Shu-Lian Liu, Hua-Jie Lu, Meng-Lan Guo, Xiao-Min Niu, Shiwali Vinita, Shuang Ning, Li-Ping Han","doi":"10.1186/s12905-025-03700-8","DOIUrl":"10.1186/s12905-025-03700-8","url":null,"abstract":"<p><strong>Background: </strong>Adenomyosis is a common gynecological disorder characterized by the invasion of endometrial tissue into the myometrium, resulting in severe dysmenorrhea and menorrhagia. This study aimed to explore the role of SMOC2 (SPARC related modular calcium binding 2), an extracellular matrix (ECM) -associated protein, in the pathogenesis of adenomyosis and its potential as a therapeutic target.</p><p><strong>Methods: </strong>We conducted a clinical study involving 35 patients diagnosed with adenomyosis and 30 controls. Ectopic endometrial tissue samples were collected and analyzed using immunohistochemistry (IHC), Masson staining, and cell culture techniques. The proliferative effect of SMOC2 on cells was evaluated using CCK- 8 assay, while the expression of SMOC2 and epithelial-mesenchymal transition (EMT) was assessed using real-time PCR and western blot analysis.</p><p><strong>Results: </strong>SMOC2 expression was significantly higher in the ectopic endometrial tissue of adenomyosis patients compared to controls. SMOC2 could promote cell proliferation. Overexpression of SMOC2 significantly upregulated mesenchymal markers N-cadherin and α-SMA, and downregulated epithelial marker E-cadherin. Conversely, knocking down SMOC2 with siRNA reversed these effects. These findings indicate that SMOC2 promotes EMT in adenomyotic stromal cells. Additionally, SMOC2 also activated the MMP9 signaling pathway, which plays a crucial role in the extracellular matrix (ECM) remodeling.</p><p><strong>Conclusions: </strong>SMOC2 appears to be a key regulator in the pathogenesis of adenomyosis, promoting ECM remodeling and EMT, both of which are characteristic of the disease. Targeting SMOC2 may provide a novel therapeutic strategy for the treatment of adenomyosis.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"155"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and survival benefits of bilateral breast-conserving surgery in patients with metachronous bilateral breast cancer.","authors":"Qiuyan Huang, Qingzhong Lin, Yinlong Yang","doi":"10.1186/s12905-025-03685-4","DOIUrl":"10.1186/s12905-025-03685-4","url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the temporal trends and survival outcomes of bilateral breast-conserving surgery (BCS) in women diagnosed with metachronous bilateral breast cancer (MBBC) in the USA from 2000 to 2019.</p><p><strong>Methods: </strong>Patients with stage T0-T3 and stage 0-III MBBC who underwent unilateral BCS on one side and different surgical procedures on the contralateral side from 2000 to 2019 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The Cochrane-Armitage test for trend was employed to assess the trends in contralateral breast surgical procedures, including BCS, mastectomy (M) and breast-reconstruction (BR). Overall survival (OS) and breast cancer-specific survival (BCSS) were analyzed using Kaplan-Meier curves and univariate and multivariate Cox proportional hazards regression analyses. Since BR is typically performed following M, survival data for the BR and M groups were combined and collectively analyzed as the M group.</p><p><strong>Results: </strong>A total of 9571 patients with stage T0-T3 and stage 0-III who underwent unilateral BCS were included in this study, with 75.84% (n = 7,259) opting for BCS treatment. The proportion of BCS was decreased significantly from 90.79% in 2000 to 74.04% in 2019 (P < 0.0001). Older age was positively correlated with BCS, while recent diagnosis, late T stage, lymph node metastasis, invasive lobular carcinoma and chemotherapy were negatively correlated with BCS. Kaplan-Meier survival analysis indicated that BCS patients had better OS (P < 0.001) and BCSS (P < 0.001) compared with patients receiving M. Univariate Cox analysis indicated that BCS showed significant statistical differences in both OS and BCSS. Specifically, the hazard ratio (HR) for OS and BCSS were 0.717 (95% CI 0.649-0.791, P < 0.001) and 0.484 (95% CI 0.422-0.556, P < 0.001), respectively. Multivariate Cox analysis indicated that BCS was not an independent prognostic factor for OS (HR = 1.012, 95% CI 0.904-1.132, P > 0.05), suggesting no significant difference in OS between the BCS and M groups. Conversely, BCS was an independent favorable prognostic factor for BCSS (HR = 0.746, 95% CI 0.634, 0.877; P < 0.05).</p><p><strong>Conclusion: </strong>Despite the initial high utilization of BCS in MBBC patients, our study revealed a decline in its usage over the course of the study period. Importantly, this decrease did not impact OS, suggesting the safety of BCS for MBBC patients. In light of these findings, clinicians are encouraged to recommend BCS for eligible MBBC patients, emphasizing its viability as a treatment option.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"152"},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The health-promoting lifestyle and its relationship with the impacts of endometriosis on women's lives in Iran, 2022: a cross-sectional study.","authors":"Sanaz Mollazadeh, Khadijeh Mirzaii Najmabadi, Mojgan Mirghafourvand, Talat Khadivzadeh, Javad Moghri, Leili Hafizi","doi":"10.1186/s12905-025-03696-1","DOIUrl":"10.1186/s12905-025-03696-1","url":null,"abstract":"<p><strong>Background: </strong>Endometriosis is a chronic gynecological disease that affects various aspects of the women's lives, so considering its impacts and improving health-promoting lifestyle is important. The present study aimed to determine the association between health-promoting lifestyle and endometriosis impacts on women lives.</p><p><strong>Methods: </strong>This cross-sectional study was conducted on 200 women with endometriosis in the endometriosis clinic of Imam Reza Hospital in Mashhad-Iran. The data was collected using the HPLP-II (health-promoting lifestyle) and EIQ tools (endometriosis impact questionnaire), as well as socio-demographic and obstetrics characteristics questionnaires. Data was analyzed in SPSS 21 software. Spearman's test was used to investigate the correlation between health-promoting behaviors and the impacts of endometriosis on women's lives.</p><p><strong>Results: </strong>In the total of three recall periods of EIQ, there was a negative significant correlation between the overall lifestyle score of HPLP and the physical impact of endometriosis disease (r=-0.23; P < 0.001), the psychological impact (r=-0.29; P < 0.001), social impact (r=-0.30; P < 0.001), as well as education dimensions of EIQ (r=-0.52; P = 0.016).</p><p><strong>Conclusions: </strong>Considering the negative significant correlation between the health-promoting lifestyle and the physical, psychological, social, as well as education impacts of endometriosis, adopting a healthy lifestyle for women with endometriosis seems useful and necessary. In future studies, it is recommended to provide information for writing a program with a clear and concise explanation for these women to improve affected women's lives.</p>","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":"25 1","pages":"153"},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}